- Home
- CROX vs BIO Comparison
CROX vs BIO Comparison
Compare CROX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- BIO
- Stock Information
- Founded
- CROX 1999
- BIO 1952
- Country
- CROX United States
- BIO United States
- Employees
- CROX N/A
- BIO N/A
- Industry
- CROX Shoe Manufacturing
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- CROX Consumer Discretionary
- BIO Industrials
- Exchange
- CROX Nasdaq
- BIO Nasdaq
- Market Cap
- CROX 8.3B
- BIO 9.1B
- IPO Year
- CROX 2006
- BIO N/A
- Fundamental
- Price
- CROX $110.92
- BIO $337.68
- Analyst Decision
- CROX Buy
- BIO Strong Buy
- Analyst Count
- CROX 15
- BIO 4
- Target Price
- CROX $146.21
- BIO $414.00
- AVG Volume (30 Days)
- CROX 1.3M
- BIO 180.4K
- Earning Date
- CROX 10-29-2024
- BIO 10-30-2024
- Dividend Yield
- CROX N/A
- BIO N/A
- EPS Growth
- CROX 27.09
- BIO N/A
- EPS
- CROX 13.79
- BIO N/A
- Revenue
- CROX $4,072,432,000.00
- BIO $2,580,209,000.00
- Revenue This Year
- CROX $4.94
- BIO N/A
- Revenue Next Year
- CROX $3.05
- BIO $3.61
- P/E Ratio
- CROX $8.09
- BIO N/A
- Revenue Growth
- CROX 3.17
- BIO N/A
- 52 Week Low
- CROX $85.71
- BIO $262.12
- 52 Week High
- CROX $165.32
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- CROX 52.07
- BIO 49.20
- Support Level
- CROX $108.66
- BIO $329.08
- Resistance Level
- CROX $113.10
- BIO $351.08
- Average True Range (ATR)
- CROX 3.04
- BIO 9.89
- MACD
- CROX 0.86
- BIO 0.70
- Stochastic Oscillator
- CROX 73.08
- BIO 55.68
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include the Americas, Asia Pacific, and EMEA.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.